Impact of MiRSNPs on Survival and Progression in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

被引:61
作者
Fernandez de Larrea, Carlos [1 ]
Navarro, Alfons [2 ]
Tejero, Rut [2 ]
Tovar, Natalia [1 ]
Diaz, Tania [2 ]
Teresa Cibeira, Maria [1 ]
Rosinol, Laura [1 ]
Ferrer, Gerardo [2 ]
Rovira, Montserrat [1 ]
Rozman, Maria [3 ]
Monzo, Mariano [2 ]
Blade, Joan [1 ]
机构
[1] Univ Barcelona, Hosp Clin, Dept Hematol, Amyloidosis & Myeloma Unit, Barcelona, Spain
[2] Univ Barcelona, Sch Med, Human Anat Unit, Mol Oncol & Embryol Lab, Barcelona, Spain
[3] Univ Barcelona, IDIBAPS, Hosp Clin, Hematopathol Unit, Barcelona, Spain
关键词
MICRORNA EXPRESSION; HUMAN CANCERS; GENES; POLYMORPHISMS; SUSCEPTIBILITY; LEUKEMIA; RISK;
D O I
10.1158/1078-0432.CCR-12-0191
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A distinctive new group of polymorphisms is constituted by single-nucleotide polymorphism (SNP) in miRNA processing machinery in miRNA precursor molecules and in miRNA-binding sites, known as miRSNPs. The aim of this study was to ascertain the prognostic impact of six miRSNPs in patients with multiple myeloma and analyze the functional consequences. Experimental Design: One hundred and thirty-seven patients with chemosensitive multiple myeloma (73M/64F) intensified with autologous stem cell transplantation (ASCT) were studied. The median follow-up was 4 years. The genes and SNPs evaluated in genomic DNA by allelic discrimination were KRT81 (rs3660), AFF1 (rs17703261), FAM179b (rs1053667), and MIR196A2 (rs11614913) for miRNA target genes and TRBP (rs784567) and XPO5 (rs11077) for miRNA biogenesis pathway. Results: Overall survival (OS) was significantly longer in patients with KRT81 rs3660 C/C variant (P = 0.037). Functional analysis showed that the presence of C variant in KRT81 30 untranslated region (UTR) is related with a reduction of the protein levels. Moreover, the reduction of KRT81 protein levels by siRNA in multiple myeloma cell lines is related to a decreased proliferation. On the other hand, OS was significantly longer in patients with C/C or A/C variant in XPO5 rs11077 (P = 0.012). There was also a significantly longer progression-free survival (PFS) for this SNP (P = 0.013). This SNP retained its prognostic impact on PFS and OS in a multivariate regression analysis (P = 0.028 and P = 0.014, respectively). Conclusion: This is the first report that relates miRSNPs with prognosis in multiple myeloma either in a keratin gene (KRT81), target of diverse miRNA multiple myeloma clusters, or in the miRNA biogenesis pathway-related protein exportin-5. Clin Cancer Res; 18(13); 3697-704. (C)2012 AACR.
引用
收藏
页码:3697 / 3704
页数:8
相关论文
共 50 条
  • [41] Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis
    Rush, Carolina A.
    Atkins, Harold L.
    Freedman, Mark S.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2019, 9 (03):
  • [42] The Impact of CD34+Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma
    Lebel, Eyal
    Lajkosz, Katherine
    Masih-Khan, Esther
    Reece, Donna
    Trudel, Suzanne
    Tiedemann, Rodger
    Prica, Anca
    Kukreti, Vishal
    Chen, Christine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (11) : 850 - 856
  • [43] Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
    Kawamura, Koji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (02) : 193 - 200
  • [44] Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma
    Bruno, Benedetto
    Lia, Giuseppe
    Bonifazi, Francesca
    Giaccone, Luisa
    HEMATO, 2021, 2 (01): : 89 - 102
  • [45] Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
    McCarthy, Philip L.
    Owzar, Kouros
    Hofmeister, Craig C.
    Hurd, David D.
    Hassoun, Hani
    Richardson, Paul G.
    Giralt, Sergio
    Stadtmauer, Edward A.
    Weisdorf, Daniel J.
    Vij, Ravi
    Moreb, Jan S.
    Callander, Natalie Scott
    Van Besien, Koen
    Gentile, Teresa
    Isola, Luis
    Maziarz, Richard T.
    Gabriel, Don A.
    Bashey, Asad
    Landau, Heather
    Martin, Thomas
    Qazilbash, Muzaffar H.
    Levitan, Denise
    McClune, Brian
    Schlossman, Robert
    Hars, Vera
    Postiglione, John
    Jiang, Chen
    Bennett, Elizabeth
    Barry, Susan
    Bressler, Linda
    Kelly, Michael
    Seiler, Michele
    Rosenbaum, Cara
    Hari, Parameswaran
    Pasquini, Marcelo C.
    Horowitz, Mary M.
    Shea, Thomas C.
    Devine, Steven M.
    Anderson, Kenneth C.
    Linker, Charles
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) : 1770 - 1781
  • [46] Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma
    Vekemans, Marie-Christiane
    Michaux, Lucienne
    Van den Neste, Eric
    Ferrant, Augustin
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (04) : 616 - 618
  • [47] Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data
    Schenone, Daniela
    Dominietto, Alida
    Campi, Cristina
    Frassoni, Francesco
    Cea, Michele
    Aquino, Sara
    Angelucci, Emanuele
    Rossi, Federica
    Torri, Lorenzo
    Bignotti, Bianca
    Tagliafico, Alberto Stefano
    Piana, Michele
    DIAGNOSTICS, 2021, 11 (10)
  • [48] The Role of Ferritin and Folate in Determining Stem Cell Collection for Autologous Stem Cell Transplant in Multiple Myeloma
    Weeks, Charles J.
    Mian, Mohammad
    Stokes, Michael
    Gold, Matthew
    Shah, Anvay
    Vuppala, Rohan
    Kim, Katherine J.
    Simon, Abigayle B.
    Cortes, Jorge
    Jillela, Anand
    Kota, Vamsi
    HEMATOLOGY REPORTS, 2025, 17 (01)
  • [49] Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma
    Chen, Yao
    Lu, Jin
    Xu, Lan-Ping
    Chen, Huan
    Zhang, Xiao-Hui
    Wang, Feng-Rong
    Chen, Yu-Hong
    Wang, Yu
    Liu, Kai-Yan
    Huang, Xiao-Jun
    BONE MARROW TRANSPLANTATION, 2018, 53 (04) : 507 - 510
  • [50] Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era
    Takamatsu, Hiroyuki
    Honda, Sumihisa
    Miyamoto, Toshihiro
    Yokoyama, Kenji
    Hagiwara, Shotaro
    Ito, Toshiro
    Tomita, Naoto
    Iida, Shinsuke
    Iwasaki, Toshihiro
    Sakamaki, Hisashi
    Suzuki, Ritsuro
    Sunami, Kazutaka
    CANCER SCIENCE, 2015, 106 (02) : 179 - 185